Company profile: KAI Pharmaceuticals
1.1 - Company Overview
Company description
- Provider of novel therapeutics through drug discovery and development, with multiple clinical-stage programs in cardiovascular disease, kidney disease, and pain; lead candidate KAI-9803 is in Phase 2b (PROTECTION AMI) evaluating reduction of myocardial injury in heart attack.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to KAI Pharmaceuticals
Reata Pharmaceuticals
HQ: United States
Website
- Description: Provider of biopharmaceutical therapies for cancer, inflammation, neurodegenerative, renal, cardiovascular, and autoimmune diseases, including antioxidant and inflammation-modulating drugs and agents that correct protein misfolding. Offers Skyclarys (omaveloxolone), an FDA-approved treatment for Friedreich's Ataxia in patients 16+.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Reata Pharmaceuticals company profile →
Bliss Biopharma
HQ: China
Website
- Description: Provider of tumor-targeting and immunotherapy therapeutics, focused on antibody-drug conjugates (ADCs). Offers BB-1701, an anti-HER2 ADC in international multi-center trials for HER2-positive solid tumors, and a diverse ADC pipeline in preclinical and clinical stages. Operates in-house, GMP-compliant antibody and ADC manufacturing to support clinical development and early commercialization.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Bliss Biopharma company profile →
Propagenix
HQ: United States
Website
- Description: Provider of healthcare technology platforms for translational biomedical research, including EpiX technology to expand primary epithelial cells without genetic modification, CR feeder-cell culture to replicate epithelial cells, engineered bi-layered skin constructs, airway epithelium models and theranostic assays, and collaborative and sponsored research for drug discovery and toxicology screening.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Propagenix company profile →
Mavu Pharma
HQ: United States
Website
- Description: Provider of non-nucleotide, conditional modulators of the STING pathway to treat cancer and infectious disease.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Mavu Pharma company profile →
Cequent Pharmaceuticals
HQ: United States
Website
- Description: Provider of TransKingdom RNA interference (tkRNAi) therapeutics using non-pathogenic bacteria to deliver RNAi into cells to silence disease-causing genes, with pre-clinical drug candidates for colon cancer prevention and inflammatory bowel disease, targeting a wide range of human diseases from inflammatory conditions to cancer.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cequent Pharmaceuticals company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for KAI Pharmaceuticals
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to KAI Pharmaceuticals
2.2 - Growth funds investing in similar companies to KAI Pharmaceuticals
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for KAI Pharmaceuticals
4.2 - Public trading comparable groups for KAI Pharmaceuticals
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →